- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
One For Choosing Wisely in Breast Cancer
A study presented at the San Antonio Breast Cancer Symposium showed that Herceptin may not complement chemotherapy in breast tumors with a high level of immune infiltration.
HER2-positive breast cancers with a high level of immune cell infiltration might not benefit from the addition of trastuzumab (Herceptin) to chemotherapy, a trial analysis suggested.
The 10% of patients with stromal tumor-infiltrating lymphocyte-predominant breast cancer in the Alliance N9831 trial showed similar recurrence-free survival whether they received chemotherapy alone or with trastuzumab (10-year rate 90.9% versus 80.0%, P = .21), Edith A. Perez, MD, of the Mayo Clinic in Jacksonville, Florida, and colleagues found.
The rest showed, as expected, significantly better recurrence-free survival with addition of trastuzumab (10-year rate 79.6% vs 64.3%, hazard ratio .49, P = .0003), they reported at the San Antonio Breast Cancer Symposium.
Link to the complete report: http://bit.ly/1GjDd6y
Source: Medpage Today
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
